1.
Alessi, D.R., et al., Characterization of a 3-phosphoinositide-dependent protein
kinase which phosphorylates and activates protein kinase Balpha. Curr Biol, 1997.
7(4): p. 261-9.
2.
Stephens, L., et al., Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-
trisphosphate-dependent activation of protein kinase B. Science, 1998. 279(5351): p.
710-4.
3.
Vanhaesebroeck, B. and D.R. Alessi, The PI3K-PDK1 connection: more than just a
road to PKB. Biochem J, 2000. 346 Pt 3(Pt 3): p. 561-76.
4.
Casamayor, A., N.A. Morrice, and D.R. Alessi, Phosphorylation of Ser-241 is essential
for the activity of 3-phosphoinositide-dependent protein kinase-1: identification of
five sites of phosphorylation in vivo. Biochem J, 1999. 342 ( Pt 2)(Pt 2): p. 287-92.
5.
Alessi, D.R., et al., 3-Phosphoinositide-dependent protein kinase-1 (PDK1):
structural and functional homology with the Drosophila DSTPK61 kinase. Curr Biol,
1997. 7(10): p. 776-89.
6.
Fujita, N., et al., Involvement of Hsp90 in signaling and stability of 3-
phosphoinositide-dependent kinase-1. J Biol Chem, 2002. 277(12): p. 10346-53.
7.
Grillo,
S.,
et
al.,
Peroxovanadate
induces
tyrosine
phosphorylation
of
phosphoinositide-dependent protein kinase-1 potential involvement of src kinase.
Eur J Biochem, 2000. 267(22): p. 6642-9.
8.
Park, J., et al., Identification of tyrosine phosphorylation sites on 3-phosphoinositide-
dependent protein kinase-1 and their role in regulating kinase activity. J Biol Chem,
2001. 276(40): p. 37459-71.
9.
Prasad, N., et al., Oxidative stress and vanadate induce tyrosine phosphorylation of
phosphoinositide-dependent kinase 1 (PDK1). Biochemistry, 2000. 39(23): p. 6929-35.
10.
Sato, S., N. Fujita, and T. Tsuruo, Regulation of kinase activity of 3-phosphoinositide-
dependent protein kinase-1 by binding to 14-3-3. J Biol Chem, 2002. 277(42): p.
39360-7.
11.
Yang, K.J., et al., Regulation of 3-phosphoinositide-dependent protein kinase-1
(PDK1) by Src involves tyrosine phosphorylation of PDK1 and Src homology 2 domain
binding. J Biol Chem, 2008. 283(3): p. 1480-1491.
12.
Lerman, M.I. and J.D. Minna, The 630-kb lung cancer homozygous deletion region
on human chromosome 3p21.3: identification and evaluation of the resident
candidate tumor suppressor genes. The International Lung Cancer Chromosome
3p21.3 Tumor Suppressor Gene Consortium. Cancer Res, 2000. 60(21): p. 6116-33.
55
13.
Sekido, Y., et al., Cloning of a breast cancer homozygous deletion junction narrows
the region of search for a 3p21.3 tumor suppressor gene. Oncogene, 1998. 16(24): p.
3151-7.
14.
Ji, L., et al., Expression of several genes in the human chromosome 3p21.3
homozygous deletion region by an adenovirus vector results in tumor suppressor
activities in vitro and in vivo. Cancer Res, 2002. 62(9): p. 2715-20.
15.
Schenk, P.W., et al., Anticancer drug resistance induced by disruption of the
Saccharomyces cerevisiae NPR2 gene: a novel component involved in cisplatin- and
doxorubicin-provoked cell kill. Mol Pharmacol, 2003. 64(2): p. 259-68.
16.
Ueda, K., et al., The 3p21.3 tumor suppressor NPRL2 plays an important role in
cisplatin-induced resistance in human non-small-cell lung cancer cells. Cancer Res,
2006. 66(19): p. 9682-90.
17.
Balendran, A., et al., Evidence that 3-phosphoinositide-dependent protein kinase-1
mediates phosphorylation of p70 S6 kinase in vivo at Thr-412 as well as Thr-252. J
Biol Chem, 1999. 274(52): p. 37400-6.
18.
Fiory, F., et al., Tyrosine phosphorylation of phosphoinositide-dependent kinase 1 by
the insulin receptor is necessary for insulin metabolic signaling. Mol Cell Biol, 2005.
25(24): p. 10803-14.
19.
Kim, D.W., et al., RET/PTC (rearranged in transformation/papillary thyroid
carcinomas) tyrosine kinase phosphorylates and activates phosphoinositidedependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinaseindependent pathway to activate PDK1. Mol Endocrinol, 2003. 17(7): p. 1382-94.
20.
Taniyama, Y., et al., Pyk2- and Src-dependent tyrosine phosphorylation of PDK1
regulates focal adhesions. Mol Cell Biol, 2003. 23(22): p. 8019-29.
21.
Balendran, A., et al., PDK1 acquires PDK2 activity in the presence of a synthetic
peptide derived from the carboxyl terminus of PRK2. Curr Biol, 1999. 9(8): p. 393404.
22.
Remy, I. and S.W. Michnick, Regulation of apoptosis by the Ft1 protein, a new
modulator of protein kinase B/Akt. Mol Cell Biol, 2004. 24(4): p. 1493-504.
23.
Biscardi, J.S., et al., c-Src-mediated phosphorylation of the epidermal growth factor
receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J
Biol Chem, 1999. 274(12): p. 8335-43.
24.
Mao, W., et al., Activation of c-Src by receptor tyrosine kinases in human colon cancer
cells with high metastatic potential. Oncogene, 1997. 15(25): p. 3083-90.
25.
Rokudai, S., et al., Involvement of FKHR-dependent TRADD expression in
chemotherapeutic drug-induced apoptosis. Mol Cell Biol, 2002. 22(24): p. 8695-708.
56
26.
Sato, S., N. Fujita, and T. Tsuruo, Interference with PDK1-Akt survival signaling
pathway by UCN-01 (7-hydroxystaurosporine). Oncogene, 2002. 21(11): p. 1727-38.
27.
Tsuruo, T., et al., Molecular targeting therapy of cancer: drug resistance, apoptosis
and survival signal. Cancer Sci, 2003. 94(1): p. 15-21.
28.
Xie, Z., et al., Transformation of mammary epithelial cells by 3-phosphoinositide-
dependent protein kinase-1 activates beta-catenin and c-Myc, and down-regulates
caveolin-1. Cancer Res, 2003. 63(17): p. 5370-5.
29.
Zeng, X., H. Xu, and R.I. Glazer, Transformation of mammary epithelial cells by 3-
phosphoinositide-dependent protein kinase-1 (PDK1) is associated with the induction
of protein kinase Calpha. Cancer Res, 2002. 62(12): p. 3538-43.
30.
Liu, L.Z., et al., AKT1 amplification regulates cisplatin resistance in human lung
cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer
Res, 2007. 67(13): p. 6325-32.
31.
Pinner, S. and E. Sahai, PDK1 regulates cancer cell motility by antagonising
inhibition of ROCK1 by RhoE. Nat Cell Biol, 2008. 10(2): p. 127-37.
32.
Xie, Z., et al., 3-phosphoinositide-dependent protein kinase-1 (PDK1) promotes
invasion and activation of matrix metalloproteinases. BMC Cancer, 2006. 6: p. 77.
33.
Mortality, G.B.D. and C. Causes of Death, Global, regional, and national life
expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death,
1980-2015: a systematic analysis for the Global Burden of Disease Study 2015.
Lancet, 2016. 388(10053): p. 1459-1544.
34.
Palmer, S.C., et al., Comparative efficacy and safety of blood pressure-lowering
agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet,
2015. 385(9982): p. 2047-56.
35.
Pedersen, H.L., et al., Murine and Human Lupus Nephritis: Pathogenic Mechanisms
and Theoretical Strategies for Therapy. Semin Nephrol, 2015. 35(5): p. 427-38.
36.
van der Meer, J.H., T. van der Poll, and C. van 't Veer, TAM receptors, Gas6, and
protein S: roles in inflammation and hemostasis. Blood, 2014. 123(16): p. 2460-9.
37.
Lew, E.D., et al., Differential TAM receptor-ligand-phospholipid interactions delimit
differential TAM bioactivities. Elife, 2014. 3.
38.
Rothlin, C.V. and G. Lemke, TAM receptor signaling and autoimmune disease. Curr
Opin Immunol, 2010. 22(6): p. 740-6.
39.
Nagata, K., et al., Identification of the product of growth arrest-specific gene 6 as a
common ligand for Axl, Sky, and Mer receptor tyrosine kinases. J Biol Chem, 1996.
271(47): p. 30022-7.
40.
Myers, S.H., V.G. Brunton, and A. Unciti-Broceta, AXL Inhibitors in Cancer: A
57
Medicinal Chemistry Perspective. J Med Chem, 2016. 59(8): p. 3593-608.
41.
Pettazzoni, P., et al., Genetic events that limit the efficacy of MEK and RTK inhibitor
therapies in a mouse model of KRAS-driven pancreatic cancer. Cancer Res, 2015.
75(6): p. 1091-101.
42.
Fiebeler, A., et al., Growth arrest specific protein 6/Axl signaling in human
inflammatory renal diseases. Am J Kidney Dis, 2004. 43(2): p. 286-95.
43.
Lee, I.J., et al., Growth arrest-specific gene 6 (Gas6) levels are elevated in patients
with chronic renal failure. Nephrol Dial Transplant, 2012. 27(11): p. 4166-72.
44.
Yanagita, M., Gas6, warfarin, and kidney diseases. Clin Exp Nephrol, 2004. 8(4): p.
304-9.
45.
O'Bryan, J.P., et al., The transforming receptor tyrosine kinase, Axl, is post-
translationally regulated by proteolytic cleavage. J Biol Chem, 1995. 270(2): p. 5517.
46.
Orme, J.J., et al., Heightened cleavage of Axl receptor tyrosine kinase by ADAM
metalloproteases may contribute to disease pathogenesis in SLE. Clin Immunol, 2016.
169: p. 58-68.
47.
Gong, S., et al., Plasma sMer, sAxl and GAS6 levels correlate with disease activity
and severity in lupus nephritis. Eur J Clin Invest, 2019. 49(3): p. e13064.
48.
Zhu, H., et al., The expression and clinical significance of different forms of Mer
receptor tyrosine kinase in systemic lupus erythematosus. J Immunol Res, 2014.
2014: p. 431896.
49.
Zizzo, G., et al., Circulating levels of soluble MER in lupus reflect M2c activation of
monocytes/macrophages, autoantibody specificities and disease activity. Arthritis
Res Ther, 2013. 15(6): p. R212.
50.
Ekman, C., et al., Plasma concentrations of Gas6 and sAxl correlate with disease
activity in systemic lupus erythematosus. Rheumatology (Oxford), 2011. 50(6): p.
1064-9.
51.
Wu, C.S., et al., Elevated serum level of growth arrest-specific protein 6 (Gas6) in
systemic lupus erythematosus patients is associated with nephritis and cutaneous
vasculitis. Rheumatol Int, 2014. 34(5): p. 625-9.
52.
Parodis, I., et al., Serum Axl predicts histology-based response to induction therapy
and long-term renal outcome in lupus nephritis. PLoS One, 2019. 14(2): p. e0212068.
53.
Yanagita, M., et al., Gas6 regulates mesangial cell proliferation through Axl in
experimental glomerulonephritis. Am J Pathol, 2001. 158(4): p. 1423-32.
54.
Arai, H., K. Nagai, and T. Doi, Role of growth arrest-specific gene 6 in diabetic
nephropathy. Vitam Horm, 2008. 78: p. 375-92.
58
55.
Nagai, K., et al., Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in
diabetic nephropathy. Kidney Int, 2005. 68(2): p. 552-61.
56.
Yanagita, M., et al., Essential role of Gas6 for glomerular injury in nephrotoxic
nephritis. J Clin Invest, 2002. 110(2): p. 239-46.
57.
Becker, G.J. and T.D. Hewitson, Animal models of chronic kidney disease: useful but
not perfect. Nephrol Dial Transplant, 2013. 28(10): p. 2432-8.
58.
Matsusaka, T., et al., Genetic engineering of glomerular sclerosis in the mouse via
control of onset and severity of podocyte-specific injury. J Am Soc Nephrol, 2005.
16(4): p. 1013-23.
59.
Nakanishi, Y., et al., The fibroblast growth factor receptor genetic status as a
potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective
FGFR inhibitor. Mol Cancer Ther, 2014. 13(11): p. 2547-58.
60.
Wan, X., et al., Berberine ameliorates chronic kidney injury caused by atherosclerotic
renovascular disease through the suppression of NFkappaB signaling pathway in
rats. PLoS One, 2013. 8(3): p. e59794.
61.
Souza, A.C., et al., TLR4 mutant mice are protected from renal fibrosis and chronic
kidney disease progression. Physiol Rep, 2015. 3(9).
62.
Bentley, J.P. and A.N. Hanson, The hydroxyproline of elastin. Biochim Biophys Acta,
1969. 175(2): p. 339-44.
63.
Di Lullo, G.A., et al., Mapping the ligand-binding sites and disease-associated
mutations on the most abundant protein in the human, type I collagen. J Biol Chem,
2002. 277(6): p. 4223-31.
64.
Lamouille, S., J. Xu, and R. Derynck, Molecular mechanisms of epithelial-
mesenchymal transition. Nat Rev Mol Cell Biol, 2014. 15(3): p. 178-96.
65.
de Larco, J.E. and G.J. Todaro, Epithelioid and fibroblastic rat kidney cell clones:
epidermal growth factor (EGF) receptors and the effect of mouse sarcoma virus
transformation. J Cell Physiol, 1978. 94(3): p. 335-42.
66.
Giangola, M.D., et al., Growth arrest-specific protein 6 protects against renal
ischemia-reperfusion injury. J Surg Res, 2015. 199(2): p. 572-9.
67.
Shuvy, M., et al., Raloxifene attenuates Gas6 and apoptosis in experimental aortic
valve disease in renal failure. Am J Physiol Heart Circ Physiol, 2011. 300(5): p.
H1829-40.
68.
Cohen, P.L., et al., Delayed apoptotic cell clearance and lupus-like autoimmunity in
mice lacking the c-mer membrane tyrosine kinase. J Exp Med, 2002. 196(1): p. 13540.
69.
Ye, F., et al., Retinal self-antigen induces a predominantly Th1 effector response in
59
Axl and Mertk double-knockout mice. J Immunol, 2011. 187(8): p. 4178-86.
70.
Zhen, Y., S.O. Priest, and W.H. Shao, Opposing Roles of Tyrosine Kinase Receptors
Mer and Axl Determine Clinical Outcomes in Experimental Immune-Mediated
Nephritis. J Immunol, 2016. 197(6): p. 2187-94.
71.
Zhen, Y., et al., Targeted inhibition of Axl receptor tyrosine kinase ameliorates anti-
GBM-induced lupus-like nephritis. J Autoimmun, 2018. 93: p. 37-44.
72.
Yanagita, M., et al., Gas6 induces mesangial cell proliferation via latent transcription
factor STAT3. J Biol Chem, 2001. 276(45): p. 42364-9.
73.
Mimura, I. and M. Nangaku, The suffocating kidney: tubulointerstitial hypoxia in
end-stage renal disease. Nat Rev Nephrol, 2010. 6(11): p. 667-78.
74.
Meng, X.M., D.J. Nikolic-Paterson, and H.Y. Lan, TGF-beta: the master regulator of
fibrosis. Nat Rev Nephrol, 2016. 12(6): p. 325-38.
75.
Gjerdrum, C., et al., Axl is an essential epithelial-to-mesenchymal transition-induced
regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A,
2010. 107(3): p. 1124-9.
76.
Lee, H.J., et al., Gas6/Axl pathway promotes tumor invasion through the
transcriptional activation of Slug in hepatocellular carcinoma. Carcinogenesis, 2014.
35(4): p. 769-75.
77.
Reichl, P., et al., Axl activates autocrine transforming growth factor-beta signaling in
hepatocellular carcinoma. Hepatology, 2015. 61(3): p. 930-41.
78.
Li, Y., et al., Axl as a downstream effector of TGF-beta1 via PI3K/Akt-PAK1 signaling
pathway promotes tumor invasion and chemoresistance in breast carcinoma. Tumour
Biol, 2015. 36(2): p. 1115-27.
79.
Jung, J., et al., Gas6 Prevents Epithelial-Mesenchymal Transition in Alveolar
Epithelial Cells via Production of PGE2, PGD2 and Their Receptors. Cells, 2019. 8(7).
80.
Zhou, B., et al., Troglitazone attenuates TGF-beta1-induced EMT in alveolar
epithelial cells via a PPARgamma-independent mechanism. PLoS One, 2012. 7(6): p.
e38827.
81.
Guo, J.K., et al., Increased tubular proliferation as an adaptive response to
glomerular albuminuria. J Am Soc Nephrol, 2012. 23(3): p. 429-37.
82.
Qi, R. and C. Yang, Renal tubular epithelial cells: the neglected mediator of
tubulointerstitial fibrosis after injury. Cell Death Dis, 2018. 9(11): p. 1126.
83.
Maarouf, O.H., et al., Paracrine Wnt1 Drives Interstitial Fibrosis without
Inflammation by Tubulointerstitial Cross-Talk. J Am Soc Nephrol, 2016. 27(3): p.
781-90.
84.
Sakai, N., et al., Lysophosphatidic acid signaling through its receptor initiates
60
profibrotic epithelial cell fibroblast communication mediated by epithelial cell
derived connective tissue growth factor. Kidney Int, 2017. 91(3): p. 628-641.
85.
Angelillo-Scherrer, A., et al., Deficiency or inhibition of Gas6 causes platelet
dysfunction and protects mice against thrombosis. Nat Med, 2001. 7(2): p. 215-21.
86.
Zhong, F., et al., Tyro3 is a podocyte protective factor in glomerular disease. JCI
Insight, 2018. 3(22)
61
List of Publication
1.
Kurata A, Katayama R, Watanabe T, Tsuruo T, Fujita N
TUSC4/NPRL2, a novel PDK1-interacting protein, inhibits PDK1 tyrosine
phosphorylation and its downstream signaling.
Cancer Sci. 2008 Sep;99(9):1827-34.
2.
Kurata A, Tachibana Y, Takahashi T, Horiba N
Novel AXL-specific inhibitor ameliorates kidney dysfunction through the inhibition of
epithelial-to-mesenchymal transition of renal tubular cells.
PLoS One. 2020 Apr 23;15(4): e0232055.
62
...
論文の公開元へ
